← Back to Search

Imaging

Dixon MRI for Prostate Cancer

N/A
Waitlist Available
Led By Vikas Kundra
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Biopsy proven prostate cancer patients who are scheduled to undergo prostatectomy.
Patient who is scheduled to have a clinically indicated staging endorectal prostate MRI exam.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 1 year
Awards & highlights
No Placebo-Only Group

Study Summary

This trial uses MRI with Dixon-based imaging to detect prostate cancer. Researchers hope to learn if this will produce better images than the standard MRI scan.

Who is the study for?
This trial is for men with biopsy-proven prostate cancer who have consented to participate, are scheduled for prostate removal surgery (prostatectomy), and a standard MRI scan. It's not open to those who've had hormone or radiation therapy affecting the pelvis or prostate, prefer other treatments over surgery, or can't have MRIs due to metal implants or pacemakers.Check my eligibility
What is being tested?
The study is testing whether a modified MRI technique using Dixon based imaging sequences can provide better images of prostate cancer compared to the usual MRI scans. The goal is to see if this new scanning method improves the detection and visualization of prostate tumors.See study design
What are the potential side effects?
Since this trial involves an investigational imaging technique rather than a drug, there are no direct side effects like you'd expect from medication. However, typical MRI-related concerns such as discomfort from lying still may occur.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have prostate cancer confirmed by biopsy and will have surgery to remove my prostate.
Select...
I am scheduled for a prostate MRI to check the cancer stage.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Detection of at least one or more prostate lesions with Dixon sequencing

Side effects data

From 2022 Phase 3 trial • 53 Patients • NCT00033293
19%
87900-Vomiting(targeted toxicity)
15%
11400-Agitation
8%
11600-Alanine aminotransferase increased
8%
16800-Bladder infection
8%
44800-Infections and infestations - Other specify
8%
58700-Nystagmus
4%
15000-Aspartate aminotransferase increased
4%
88500-White blood cell decreased
4%
15300-Ataxia
4%
33900-Fever
4%
25700-Diarrhea
4%
43100-Hypokalemia
4%
69700-Rash maculo-papular(targeted toxicity)
4%
13200-Anemia
4%
33300-Febrile neutropenia
4%
57600-Nausea(targeted toxicity)
4%
20500-Catheter related infection
4%
58300-Neutrophil count decreased
4%
41300-Hypercalcemia
4%
41400-Hyperglycemia(targeted toxicity)
4%
41600-Hyperkalemia
4%
42600-Hypoalbuminemia
4%
42700-Hypocalcemia
4%
64400-Personality change
4%
41500-Hyperhidrosis
4%
13500-Anorexia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Arm I (Chemotherapy, Immunoglobulin Therapy)
Arm II (Chemotherapy, Observation)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Diagnostic (standard MRI, Dixon MRI)Experimental Treatment2 Interventions
Patients undergo MRI with additional Dixon based sequences with fat and water over a total of 49 minutes.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Magnetic Resonance Imaging
2017
Completed Phase 3
~1250

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,943 Previous Clinical Trials
1,775,265 Total Patients Enrolled
94 Trials studying Prostate Cancer
29,557 Patients Enrolled for Prostate Cancer
National Cancer Institute (NCI)NIH
13,576 Previous Clinical Trials
41,224,124 Total Patients Enrolled
558 Trials studying Prostate Cancer
506,213 Patients Enrolled for Prostate Cancer
Vikas KundraPrincipal InvestigatorM.D. Anderson Cancer Center
5 Previous Clinical Trials
353 Total Patients Enrolled

Media Library

Dixon MRI (Imaging) Clinical Trial Eligibility Overview. Trial Name: NCT05047965 — N/A
Prostate Cancer Research Study Groups: Diagnostic (standard MRI, Dixon MRI)
Prostate Cancer Clinical Trial 2023: Dixon MRI Highlights & Side Effects. Trial Name: NCT05047965 — N/A
Dixon MRI (Imaging) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05047965 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still opportunities to become involved in this scientific investigation?

"The clinical trial, initially posted on April 25th 2013 and last updated on September 8th 2021 is not recruiting patients. However, there are an abundance of other medical studies currently enrolling new participants."

Answered by AI
~14 spots leftby Feb 2027